CD44 and neoplasm: In patients treated with neoadjuvant letrozole, CD44+/CD24− mammosphere forming cells, representative of CSCs, were increased and the remaining tumour cells appeared to have a mesenchymal phenotype consistent with the more aggressive, basal-like type of breast cancer [9].